Other languages SK Biopharmaceuticals Co., Ltd.

Equities

A326030

KR7326030004

End-of-day quote Korea S.E. Other stock markets 23:00:00 25/04/2024 BST			5-day change	1st Jan Change
83,500 ^KRW	+0.24%		+0.97%	-16.83%

01-30	SK Biopharmaceuticals Swings to Profit in Q4	MT
2023	SK Group Advances Net Zero Transition via Key Renewable Energy Deal	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SK Biopharmaceuticals Swings to Profit in Q4	01-30
SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	12/10/23
Sk Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data on IKZF2 Protein Degrader Program and Moped Molecular Glue Screening Platform At the 20Th Annual Discovery on Target Conference	27/09/23
SK Biopharmaceuticals Co., Ltd. acquired remaining 605 stake in ProteoVant Sciences, Inc. from Roivant Sciences Ltd..	30/08/23
South Korean Shares Close Higher on Optimism Over China's One-Year Loan Prime Rate Cut; SK Biopharma Adds 2%	21/08/23
SK Biopharmaceuticals Continues to Report Losses in Q2	11/08/23
SK Biopharmaceuticals Assembles Board of Prominent Experts to Boost Growth, Innovation	03/08/23
SK Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23
SK Biopharmaceuticals Narrows Loss in Q1	12/05/23
SK Biopharmaceuticals Swings to Loss in Q4	09/02/23
SK Biopharmaceuticals Co. Ltd Partner Angelini Pharma Launches Cenobamate in France	08/12/22
Seoul National University Bundang Hospital Presents Study of SK Biopharmaceuticals' Seizure Detection Wearable Device At AES 2022	04/12/22
SK Biopharmaceuticals Appoints Donghoon Lee as President of Company and U.S. Subsidiary Effective January 1, 2023	01/12/22
SK Biopharmaceuticals and SK Life Science Announces Executive Changes	01/12/22
SK Biopharmaceuticals Receives Korea Drug Development Fund Investment Grant to Develop Novel Oncology Candidate, SKL27969	13/11/22
SK Biopharmaceuticals, Co., Ltd., Eurofarma Enters into Licensing Agreement for Cenobamate in Latin America	14/07/22
SK Biopharmaceuticals Swings to Loss in Q1	13/05/22
BIORCHESTRA and SK Biopharmaceuticals Collaborate to Develop Mirna-Targeted Therapeutics	05/01/22
Health Care Stocks Advance Premarket Thursday	23/12/21
Endo International Signs Agreement to Commercialize SK Biopharmaceuticals' Cenobamate in Canada	23/12/21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages SK Biopharmaceuticals Co., Ltd.

Equities

A326030

KR7326030004

Other languages

Filters